Longevity, Cellular Energy, and Biological Age

Evidence Review

Animal Research: Lifespan and Healthspan in Mice

The foundational study by Asadi Shahmirzadi et al. (PMID 32877690), published in Cell Metabolism in 2020, is the most important preclinical work on AKG. The researchers supplemented middle-aged C57BL/6 mice with Ca-AKG starting at approximately 18 months of age (equivalent to late middle age in humans). Key findings:

• Female mice showed a median lifespan extension of approximately 12% and a maximum lifespan extension of about 10%
• Both male and female mice showed significant improvements in healthspan metrics, including reduced frailty scores on validated frailty indexes
• Systemic inflammatory cytokines (TNF-α, IL-6, CXCL1) were significantly reduced
• Collagen and hair coat quality — physical markers of aging — were measurably improved
• Importantly, the supplement compressed morbidity: mice lived healthier for longer before dying, rather than extending the period of illness

The mechanism was attributed to ATP synthase inhibition leading to mTOR suppression, combined with reduced inflammation via IL-10 induction. This study used Ca-AKG in the diet at a dose equivalent to roughly 1–2 g/day in humans.

Limitations: mouse physiology differs from human physiology; many longevity interventions that work in mice fail to translate. The result in females was stronger than in males, which may reflect differences in metabolic baseline.

Human Review: State of the Evidence

Gyanwali et al. (PMID 34952764), publishing in Trends in Endocrinology and Metabolism in 2022, reviewed all available evidence on AKG supplementation in humans. Their synthesis found:

• Strong mechanistic data in cell and animal models
• Early observational and pilot data in humans, primarily the Rejuvant retrospective analysis, which reported an average 8-year reduction in biological age (measured by TruAge DNA methylation clock) after an average of 7 months of supplementation in 42 individuals — though this was uncontrolled and retrospective
• The authors identified the need for blinded, randomized controlled trials in humans as the critical next step
• They flagged AKG's safety profile as strong relative to more aggressive longevity interventions like rapamycin

The 2022 review emphasized that AKG's epigenetic mechanism — specifically, its role as a co-factor for TET enzymes — is particularly compelling given the current understanding of DNA methylation as a driver of biological aging.

Comprehensive Review: Mechanisms and Multi-Species Evidence

Naeini et al. (PMID 36934991), published in Experimental Gerontology in 2023, reviewed evidence across C. elegans, Drosophila, mice, and humans. Key findings:

• In C. elegans, AKG supplementation extended lifespan by 50% in some experiments, acting through TOR signaling suppression
• In Drosophila, lifespan extension was associated with improved reproductive function and stress resistance
• In mice, both the Cell Metabolism results and additional studies confirmed healthspan benefits
• In humans, the mechanisms converge on the same pathways seen in animal models
• The authors concluded that AKG is one of the most biologically coherent anti-aging interventions, with the advantage that it is endogenous to human metabolism

The ABLE Trial: First Rigorous Human RCT

Sandalova et al. (PMID 37217632), published in GeroScience in 2023, described the protocol for the ABLE (Alpha-ketoglutarate supplementation and BiologicaL agE) trial — the first properly designed double-blind, placebo-controlled randomized trial of Ca-AKG in humans. Details:

• 120 participants, ages 40–60, biologically older than their chronological age based on DNA methylation age
• Intervention: 1 gram sustained-release Ca-AKG vs. placebo daily for 6 months, followed by 3 months of follow-up
• Primary outcome: change in DNA methylation age from baseline to end of intervention
• Secondary outcomes: inflammatory and metabolic blood markers, handgrip strength, leg extension strength, arterial stiffness, skin autofluorescence (a marker of advanced glycation end-products), and VO2 max
• The use of biologically older participants (elevated epigenetic age) gives the trial maximum sensitivity to detect a reversal effect

As of 2023, the trial was actively recruiting and running. Results from ABLE will be critical for determining whether the animal and observational human data translate to a real-world benefit in a controlled setting.

Bone Health: Epigenetic Mechanism Confirmed

Tian et al. (2020), published in Nature Communications, showed that AKG regulates osteogenic differentiation specifically through histone methylation. In aged mice, dietary AKG supplementation reduced bone loss by directing mesenchymal stem cells toward bone formation rather than fat cell differentiation — a switch that shifts unfavorably with aging. The researchers confirmed the mechanism by showing that inhibiting the AKG-dependent demethylase (KDM4B) blocked the protective effect. This provides a direct mechanistic link between AKG's epigenetic role and a specific tissue-level aging outcome.

Overall Evidence Assessment

AKG has some of the strongest mechanistic rationale of any emerging longevity supplement. The Krebs cycle role, the epigenetic co-factor function, the mTOR-inhibiting properties, and the anti-inflammatory effects are all well-characterized in cell biology. Animal studies consistently show lifespan and healthspan benefits. Human evidence remains limited to retrospective and observational data, but the ABLE trial will provide the first rigorous human RCT data. Safety is excellent. This is a serious research area, not a fringe supplement claim — but anyone following it should wait for the randomized trial results before drawing strong conclusions about efficacy in humans.